This site is intended for US Healthcare Professionals only
Report Adverse Event
Report Adverse Event
Contact Us
Contact Us

  • Urological disorders

    Non-muscle invasive bladder cancer (NMIBC)
    NMIBC is bladder cancer that has not spread past the lining of the bladder and has not invaded the muscle or connective tissue of the bladder wall. It is the most common type of bladder cancer; 3 out of 4 people with bladder cancer have NMIBC.1-3

    Advanced prostate cancer
    Prostate cancer is the 2nd most commonly occurring cancer in men and the 4th most common cancer overall.4

    Image

  • Unmet need

    NMIBC
    According to American Cancer Society (ACS) projections, in 2024, an estimated 83,000 Americans will be diagnosed with bladder cancer.5 Of them, more than 75% are diagnosed with high-risk non-muscle invasive bladder cancer (NMIBC) and receive initial treatment with intravesical immunotherapy Bacillus Calmette-Guérin (BCG).6 These patients will likely experience disease recurrence and progression within 1 year, and many will become unresponsive to BCG treatment.6

    Advanced prostate cancer
    In 2022, there were 230,125 new cases of prostate cancer leading to 33,746 deaths in the US.4 Cardiovascular disease (CVD) and cardiovascular (CV) risk factors increase with age, and CVD incidence and mortality are higher in men with prostate cancer compared to those without.7,8

    Image

  • Ferring research

    Gene therapy
    Most bladder cancer patients need additional treatment options after BCG, but few options are available for adult patients with high-risk NMIBC following BCG treatment who have persistent or recurrent disease.9-11 Ferring has developed a non-replicating adenoviral vector-based gene therapy that can be administered when patients first become BCG unresponsive, allowing them to remain in the care of their urologist.

    Gonadotropin releasing hormone (GnRH) antagonist
    Short-term follow-up data from a meta-analysis indicate that CV side effects are less frequent in prostate cancer patients treated with GnRH antagonists than patients treated with LHRH agonists.12
    Therefore, patients with pre-existing cardiovascular disease or other CV risk factors might be considered to be treated with antagonists if a chemical castration is chosen.12 Ferring research supports the use of GnRH antagonists to reduce testosterone levels for those with advanced prostate cancer.

    Image

  • The way forward

    Ferring develops life-changing therapies to address the unmet medical needs of patients diagnosed with bladder and other urological cancers.

    Image
Image

Urological disorders

Non-muscle invasive bladder cancer (NMIBC)
NMIBC is bladder cancer that has not spread past the lining of the bladder and has not invaded the muscle or connective tissue of the bladder wall. It is the most common type of bladder cancer; 3 out of 4 people with bladder cancer have NMIBC.1-3

Advanced prostate cancer
Prostate cancer is the 2nd most commonly occurring cancer in men and the 4th most common cancer overall.4

Image

Unmet need

NMIBC
According to American Cancer Society (ACS) projections, in 2024, an estimated 83,000 Americans will be diagnosed with bladder cancer.5 Of them, more than 75% are diagnosed with high-risk non-muscle invasive bladder cancer (NMIBC) and receive initial treatment with intravesical immunotherapy Bacillus Calmette-Guérin (BCG).6 These patients will likely experience disease recurrence and progression within 1 year, and many will become unresponsive to BCG treatment.6

Advanced prostate cancer
In 2022, there were 230,125 new cases of prostate cancer leading to 33,746 deaths in the US.4 Cardiovascular disease (CVD) and cardiovascular (CV) risk factors increase with age, and CVD incidence and mortality are higher in men with prostate cancer compared to those without.7,8

Image

Ferring research

Gene therapy
Most bladder cancer patients need additional treatment options after BCG, but few options are available for adult patients with high-risk NMIBC following BCG treatment who have persistent or recurrent disease.9-11 Ferring has developed a non-replicating adenoviral vector-based gene therapy that can be administered when patients first become BCG unresponsive, allowing them to remain in the care of their urologist.

Gonadotropin releasing hormone (GnRH) antagonist
Short-term follow-up data from a meta-analysis indicate that CV side effects are less frequent in prostate cancer patients treated with GnRH antagonists than patients treated with LHRH agonists.12
Therefore, patients with pre-existing cardiovascular disease or other CV risk factors might be considered to be treated with antagonists if a chemical castration is chosen.12 Ferring research supports the use of GnRH antagonists to reduce testosterone levels for those with advanced prostate cancer.

Image

The way forward

Ferring develops life-changing therapies to address the unmet medical needs of patients diagnosed with bladder and other urological cancers.

Explore More

Medicines
OUR MEDICINES
A range of medicines have been developed by Ferring in core therapy areas.

Which medicines have been developed?
publications
SCIENTIFIC LITERATURE
Clinical research for our medicines has spanned many years across a wide range of patient types. Browse our publications and congress materials: 

ADSTILADRIN®

(nadofaragene firadenovec-vncg) suspension

DDAVP®

(desmopressin acetate) injection

DDAVP®

(desmopressin acetate) tablets

FIRMAGON®

(degarelix) powder

Explore More

Medicines
OUR MEDICINES
A range of medicines have been developed by Ferring in core therapy areas.

Which medicines have been developed?
publications
SCIENTIFIC LITERATURE
Clinical research for our medicines has spanned many years across a wide range of patient types. Browse our publications and congress materials: